Applied Net Receivables vs Accounts Payable Analysis

APDN Stock

USD 0.60 0.01 1.64%

Applied DNA financial indicator trend analysis is way more than just evaluating Applied DNA Sciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Applied DNA Sciences is a good investment. Please check the relationship between Applied DNA Net Receivables and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Applied DNA Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

Net Receivables vs Accounts Payable

Net Receivables vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Applied DNA Sciences Net Receivables account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Applied DNA's Net Receivables and Accounts Payable is 0.48. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Applied DNA Sciences, assuming nothing else is changed. The correlation between historical values of Applied DNA's Net Receivables and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Applied DNA Sciences are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Receivables i.e., Applied DNA's Net Receivables and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.48

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Receivables

Accounts Payable

An accounting item on the balance sheet that represents Applied DNA obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Applied DNA Sciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Applied DNA's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Applied DNA Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Applied DNA Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

As of the 2nd of June 2024, Selling General Administrative is likely to drop to about 10 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 10.3 M

	2021	2022	2023	2024 (projected)
Total Revenue	18.2M	13.4M	15.4M	16.1M
Research Development	3.9M	3.7M	4.3M	4.5M

Total Revenue Research Development

Applied DNA fundamental ratios Correlations

	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Common Stock	Other Current Liab	Total Assets	Net Debt	Cash	Cash And Short Term Investments	Total Current Assets	Short Long Term Debt Total	Non Current Assets Total	Good Will	Intangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Currrent Assets Other	Property Plant And Equipment Gross	Short Term Debt	Net Receivables
Total Current Liabilities		0.43	-0.71	0.77	-0.53	0.38	0.39	0.72	0.73	-0.53	0.67	0.69	-0.44	0.59	0.59	0.58	0.41	0.56	0.53	0.58	0.58	0.34	0.39	0.48	-0.46	0.32
Total Stockholder Equity	0.43		-0.43	0.65	-0.2	0.24	0.11	0.43	0.27	-0.2	0.75	0.87	-0.85	0.76	0.76	0.9	0.04	0.48	0.32	0.68	0.54	0.01	0.48	0.36	-0.65	0.69
Retained Earnings	-0.71	-0.43		-0.68	0.26	-0.51	-0.5	-0.93	-0.67	0.26	-0.7	-0.65	0.46	-0.57	-0.57	-0.57	-0.51	-0.57	-0.61	-0.68	-0.64	-0.13	-0.17	-0.55	0.63	-0.17
Accounts Payable	0.77	0.65	-0.68		-0.34	0.32	0.18	0.61	0.48	-0.34	0.71	0.73	-0.6	0.62	0.62	0.75	0.2	0.44	0.46	0.67	0.66	0.12	0.34	0.43	-0.4	0.48
Common Stock Total Equity	-0.53	-0.2	0.26	-0.34		-0.2	-0.14	-0.29	-0.34	1.0	-0.43	-0.32	0.05	-0.15	-0.15	-0.22	0.26	-0.39	-0.08	-0.44	-0.3	-0.22	-0.28	-0.29	0.35	-0.22
Common Stock Shares Outstanding	0.38	0.24	-0.51	0.32	-0.2		0.86	0.7	0.79	-0.18	0.62	0.58	-0.43	0.6	0.6	0.29	-0.06	0.77	-0.03	0.76	0.83	-0.43	0.2	0.97	-0.3	-0.3
Non Current Liabilities Total	0.39	0.11	-0.5	0.18	-0.14	0.86		0.69	0.91	-0.13	0.6	0.55	-0.41	0.6	0.6	0.28	0.0	0.71	0.23	0.65	0.62	-0.24	0.22	0.86	-0.29	-0.3
Other Stockholder Equity	0.72	0.43	-0.93	0.61	-0.29	0.7	0.69		0.8	-0.29	0.72	0.72	-0.46	0.63	0.63	0.51	0.44	0.76	0.52	0.77	0.75	0.0	0.29	0.74	-0.65	0.08
Total Liab	0.73	0.27	-0.67	0.48	-0.34	0.79	0.91	0.8		-0.33	0.73	0.7	-0.5	0.7	0.7	0.47	0.15	0.77	0.41	0.73	0.71	-0.02	0.33	0.84	-0.39	-0.09
Common Stock	-0.53	-0.2	0.26	-0.34	1.0	-0.18	-0.13	-0.29	-0.33		-0.42	-0.31	0.04	-0.14	-0.14	-0.21	0.26	-0.38	-0.08	-0.43	-0.29	-0.23	-0.28	-0.28	0.35	-0.22
Other Current Liab	0.67	0.75	-0.7	0.71	-0.43	0.62	0.6	0.72	0.73	-0.42		0.93	-0.85	0.9	0.9	0.86	0.02	0.66	0.38	0.89	0.75	-0.09	0.38	0.71	-0.62	0.32
Total Assets	0.69	0.87	-0.65	0.73	-0.32	0.58	0.55	0.72	0.7	-0.31	0.93		-0.88	0.92	0.92	0.9	0.11	0.74	0.44	0.87	0.76	-0.01	0.52	0.69	-0.68	0.46
Net Debt	-0.44	-0.85	0.46	-0.6	0.05	-0.43	-0.41	-0.46	-0.5	0.04	-0.85	-0.88		-0.96	-0.96	-0.93	-0.02	-0.39	-0.35	-0.68	-0.63	0.18	-0.21	-0.52	0.41	-0.35
Cash	0.59	0.76	-0.57	0.62	-0.15	0.6	0.6	0.63	0.7	-0.14	0.9	0.92	-0.96		1.0	0.88	0.11	0.55	0.4	0.75	0.74	-0.21	0.25	0.68	-0.42	0.2
Cash And Short Term Investments	0.59	0.76	-0.57	0.62	-0.15	0.6	0.6	0.63	0.7	-0.14	0.9	0.92	-0.96	1.0		0.88	0.11	0.55	0.4	0.75	0.74	-0.21	0.25	0.68	-0.42	0.2
Total Current Assets	0.58	0.9	-0.57	0.75	-0.22	0.29	0.28	0.51	0.47	-0.21	0.86	0.9	-0.93	0.88	0.88		0.07	0.4	0.45	0.69	0.59	0.09	0.32	0.42	-0.56	0.58
Short Long Term Debt Total	0.41	0.04	-0.51	0.2	0.26	-0.06	0.0	0.44	0.15	0.26	0.02	0.11	-0.02	0.11	0.11	0.07		0.07	0.46	-0.12	-0.02	0.18	0.05	-0.11	-0.16	0.04
Non Current Assets Total	0.56	0.48	-0.57	0.44	-0.39	0.77	0.71	0.76	0.77	-0.38	0.66	0.74	-0.39	0.55	0.55	0.4	0.07		0.29	0.81	0.71	-0.12	0.71	0.82	-0.63	0.14
Good Will	0.53	0.32	-0.61	0.46	-0.08	-0.03	0.23	0.52	0.41	-0.08	0.38	0.44	-0.35	0.4	0.4	0.45	0.46	0.29		0.32	0.27	0.22	0.16	0.15	-0.4	0.27
Intangible Assets	0.58	0.68	-0.68	0.67	-0.44	0.76	0.65	0.77	0.73	-0.43	0.89	0.87	-0.68	0.75	0.75	0.69	-0.12	0.81	0.32		0.89	-0.13	0.42	0.86	-0.68	0.27
Property Plant And Equipment Net	0.58	0.54	-0.64	0.66	-0.3	0.83	0.62	0.75	0.71	-0.29	0.75	0.76	-0.63	0.74	0.74	0.59	-0.02	0.71	0.27	0.89		-0.29	0.16	0.91	-0.42	0.0
Current Deferred Revenue	0.34	0.01	-0.13	0.12	-0.22	-0.43	-0.24	0.0	-0.02	-0.23	-0.09	-0.01	0.18	-0.21	-0.21	0.09	0.18	-0.12	0.22	-0.13	-0.29		0.17	-0.37	-0.35	0.56
Non Currrent Assets Other	0.39	0.48	-0.17	0.34	-0.28	0.2	0.22	0.29	0.33	-0.28	0.38	0.52	-0.21	0.25	0.25	0.32	0.05	0.71	0.16	0.42	0.16	0.17		0.25	-0.54	0.55
Property Plant And Equipment Gross	0.48	0.36	-0.55	0.43	-0.29	0.97	0.86	0.74	0.84	-0.28	0.71	0.69	-0.52	0.68	0.68	0.42	-0.11	0.82	0.15	0.86	0.91	-0.37	0.25		-0.39	-0.18
Short Term Debt	-0.46	-0.65	0.63	-0.4	0.35	-0.3	-0.29	-0.65	-0.39	0.35	-0.62	-0.68	0.41	-0.42	-0.42	-0.56	-0.16	-0.63	-0.4	-0.68	-0.42	-0.35	-0.54	-0.39		-0.61
Net Receivables	0.32	0.69	-0.17	0.48	-0.22	-0.3	-0.3	0.08	-0.09	-0.22	0.32	0.46	-0.35	0.2	0.2	0.58	0.04	0.14	0.27	0.27	0.0	0.56	0.55	-0.18	-0.61

Click cells to compare fundamentals

Applied DNA Account Relationship Matchups

Applied DNA fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	4.3M	3.3M	4.2M	2.8M	3.3M	3.9M
Total Stockholder Equity	5.7M	11.1M	12.9M	5.0M	5.7M	6.0M
Retained Earnings	(269.8M)	(284.1M)	(292.5M)	(302.4M)	(272.2M)	(258.6M)
Accounts Payable	1.3M	2.0M	1.7M	1.1M	1.2M	921.1K
Common Stock Shares Outstanding	196.0K	345.9K	448.4K	653.8K	751.8K	789.4K
Non Current Liabilities Total	1.4M	31.5K	5.2M	5.9M	6.8M	7.2M
Other Stockholder Equity	275.5M	295.2M	305.4M	307.4M	353.5M	371.2M
Total Liab	5.6M	3.3M	9.4M	8.8M	10.1M	10.6M
Common Stock	5.1K	7.5K	12.9K	13.7K	12.3K	11.7K
Other Current Liab	676.4K	980.9K	1.9M	1.2M	1.1M	1.1M
Total Assets	11.3M	14.4M	22.3M	13.7M	15.7M	16.5M
Net Debt	(5.4M)	(6.6M)	(15.2M)	(5.9M)	(5.3M)	(5.1M)
Cash	7.8M	6.6M	15.2M	7.2M	8.2M	8.6M
Cash And Short Term Investments	7.8M	6.6M	15.2M	7.2M	8.2M	8.6M
Liabilities And Stockholders Equity	11.3M	14.4M	22.3M	13.7M	15.7M	16.5M
Total Current Assets	9.1M	11.3M	19.9M	8.1M	9.3M	5.0M
Non Current Assets Total	2.3M	3.1M	2.3M	5.5M	6.4M	6.7M
Intangible Assets	864.2K	734.8K	605.3K	2.7M	2.4M	2.6M
Property Plant And Equipment Net	1.3M	3.0M	2.2M	2.1M	2.4M	2.5M
Current Deferred Revenue	511.0K	281K	563.6K	76.4K	68.8K	65.4K
Non Currrent Assets Other	95.1K	95.0K	99.0K	750K	862.5K	905.6K
Property Plant And Equipment Gross	1.3M	3.8M	4.3M	5.5M	6.3M	6.6M
Net Receivables	194.3K	2.8M	3.1M	255.5K	293.8K	279.1K
Other Current Assets	599.3K	568.9K	1.1M	389.2K	447.6K	373.6K
Net Tangible Assets	(1.9M)	4.8M	11.1M	12.9M	14.8M	15.6M
Property Plant Equipment	226.2K	1.3M	3.0M	2.2M	2.6M	2.7M
Other Assets	172.0K	95.1K	95.0K	99.0K	89.1K	84.6K
Inventory	497.4K	1.4M	602.2K	330.0K	379.5K	347.2K
Other Liab	622.0K	848.3K	31.5K	5.2M	5.9M	6.2M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Applied DNA Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Applied DNA's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Applied Dna Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Applied Dna Sciences Stock:

How To Invest In Applied

Details

Is Applied Stock a good investment?

Details

What is Applied DNA's Net Worth?

Details

Largest Electronic Equipment, Instruments & Components Companies

View

Largest Technology Hardware & Equipment Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Applied DNA Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

Note that the Applied DNA Sciences information on this page should be used as a complementary analysis to other Applied DNA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Applied Stock analysis

When running Applied DNA's price analysis, check to measure Applied DNA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied DNA is operating at the current time. Most of Applied DNA's value examination focuses on studying past and present price action to predict the probability of Applied DNA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied DNA's price. Additionally, you may evaluate how the addition of Applied DNA to your portfolios can decrease your overall portfolio volatility.

	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account

Is Applied DNA's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Applied DNA. If investors know Applied will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Applied DNA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(17.63)

Revenue Per Share

7.666

Quarterly Revenue Growth

(0.79)

Return On Assets

(0.64)

Return On Equity

(2.52)

The market value of Applied DNA Sciences is measured differently than its book value, which is the value of Applied that is recorded on the company's balance sheet. Investors also form their own opinion of Applied DNA's value that differs from its market value or its book value, called intrinsic value, which is Applied DNA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Applied DNA's market value can be influenced by many factors that don't directly affect Applied DNA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Applied DNA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Applied DNA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Applied DNA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Applied Net Receivables vs Accounts Payable Analysis

Net Receivables vs Accounts Payable

Net Receivables vs Accounts Payable Correlation Analysis

Correlation Coefficient

Net Receivables

Accounts Payable

Applied DNA fundamental ratios Correlations

Applied DNA Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Applied DNA fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Applied Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 0.97	Common Stock Shares Outstanding
Total Assets	+ 0.93	Other Current Liab
Cash	+ 0.92	Total Assets
Cash And Short Term Investments	+ 0.92	Total Assets

Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt
Total Current Assets	- 0.93	Net Debt
Other Stockholder Equity	- 0.93	Retained Earnings
Net Debt	- 0.88	Total Assets
Net Debt	- 0.85	Other Current Liab